X4 Pharmaceuticals (XFOR)Chair bought ~$250K

~$250K

Approx. value · 86K sh @ $2.90

376K

Holds after · shares reported

Traded

Oct 23, 2025

Filed

Oct 28, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 15, 2025Company filing · Form 8-K · Restructuring, Executive changeAnnounced job cuts, closures or a restructuring, and changed a top executive or board member (and 1 more item)“Departure of Chief Operating Officer, Chief Commercial Officer, Chief Legal & Compliance Officer and Chief Medical Officer In connection with the workforce reduction discussed above, on September 15, 2025, the Board of Directors (the “Board”) determined to terminate the employment of Dr. Mary DiBiase, the Company’s Chief Operating Officer, Mark Baldry, the Company’s Chief Commercial Officer, and Natasha Thoren, the…”
2. Oct 23, 2025 · this disclosureInsider · 13 days before resultsChair purchased ~$250K of XFOR shares in the open market

What came next

1. Oct 23, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
2. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for X4 Pharmaceuticals

For X4 Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XFOR page.

Other recent filings by Adam R Craig, Executive Chairman

• SEC Form 4 at X4 Pharmaceuticals (XFOR)Aug 14, 2026

The full history of Adam R Craig, Executive Chairman is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at X4 Pharmaceuticals

• SEC Schedule 13GOct 7, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its XFOR page.